Xenon Pharmaceuticals shareholders approve new 2026 equity compensation plan at annual meeting

Filed June 3, 2026 · Period ending June 2, 2026 · ~1 min read

Key Changes

• medium

  Shareholders approved new 2026 Equity Incentive Plan to replace existing 2014 plan, with 68% voting in favor. Plan will govern future stock-based compensation for employees and executives.

  Item 5.07: Annual Meeting Results verify on EDGAR →
• low

  All eight directors re-elected with 95-99% approval rates. No changes to board composition. Directors serve until 2027 annual meeting.

  Item 5.07: Director Elections verify on EDGAR →
• low

  Executive compensation approved on advisory basis with 94.5% shareholder support. Shareholders also voted to conduct say-on-pay votes annually going forward.

  Item 5.07: Say-on-Pay Vote verify on EDGAR →